3D printed Stentra enhances radiation oncology care
The device from RICOH 3D for Healthcare and Kallisio is a 510(k)-cleared, patient-specific oral stent designed to improve radiation therapy for head and neck cancer (HNC) patients
Ricoh USA, a provider of integrated digital services, and Kallisio, a medical device company, have entered a partnership to manufacture and distribute Stentra, a 510(k)-cleared, patient-specific oral stent designed to improve radiation therapy for head and neck cancer (HNC) patients. Developed using technology exclusively licensed from MD Anderson Cancer Center, Stentra is engineered to protect healthy tissue by precisely displacing and immobilizing sensitive areas during treatment – allowing for more targeted and effective radiation delivery. This innovation is crucial in minimizing side effects and enhancing overall treatment outcomes.
RICOH 3D for Healthcare, a producer of patient-specific medical devices, will utilize its network of FDA-registered 3D printing facilities to produce Stentra – ensuring rapid and efficient distribution to radiation oncology teams nationwide.
“Our collaboration with Kallisio highlights our shared commitment to advancing cancer care by addressing critical needs in toxicity management,” said Gary Turner, Managing Director of RICOH 3D for Healthcare. “Stentra not only protects the tongue and other healthy tissues from exposure to radiation but also enhances the precision of radiation therapy, thereby reducing side effects and improving patient quality of life.”
Starting in October, radiation oncologists will be able to order Stentra through RICOH 3D for Healthcare’s Clinical Applications Specialists – marking a pivotal step in empowering medical professionals with advanced tools for personalized, patient-centered care.
“Partnering with RICOH 3D for Healthcare is a natural fit for our mission to transform cancer care. Ricoh’s expertise in advanced manufacturing and their robust distribution network, including point-of-care production capabilities and clinical applications team, make them an ideal partner. Together, we can ensure that Stentra reaches radiation oncology teams efficiently, enhancing treatment precision and patient outcomes on a broad scale,” said Rajan Patel, CEO of Kallisio.
